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ATP5H/KCTD2 locus is associated with Alzheimer’s disease risk
M Boada1,2,15, C Antu´nez3,15, R Ramı´rez-Lorca4,15, AL DeStefano5,6, A Gonza´lez-Pe´rez4, J Gaya´n4, J Lo´pez-Arrieta7, MA Ikram8,
I Herna´ndez1, J Marı´n3, JJ Gala´n4, JC Bis9, A Mauleo´n1, M Rosende-Roca1, C Moreno-Rey4, V Gudnasson10, FJ Moro´n4, J Velasco4,
JM Carrasco4, M Alegret1, A Espinosa1, G Vinyes1, A Lafuente1, L Vargas1, AL Fitzpatrick9, for the Alzheimer’s Disease Neuroimaging
Initiative16, LJ Launer11, ME Sa´ez4, E Va´zquez4, JT Becker12, OL Lo´pez12, M Serrano-Rı´os13, L Ta´rraga1, CM van Duijn8, LM Real4,
S Seshadri5,6,14 and A Ruiz1,4
To identify loci associated with Alzheimer disease, we conducted a three-stage analysis using existing genome-wide
association studies (GWAS) and genotyping in a new sample. In Stage I, all suggestive single-nucleotide polymorphisms (at
Po0.001) in a previously reported GWAS of seven independent studies (8082 Alzheimer’s disease (AD) cases; 12 040 controls) were
selected, and in Stage II these were examined in an in silico analysis within the Cohorts for Heart and Aging Research in Genomic
Epidemiology consortium GWAS (1367 cases and 12904 controls). Six novel signals reaching Po5 10 6 were genotyped in an
independent Stage III sample (the Fundacio´ ACE data set) of 2200 sporadic AD patients and 2301 controls. We identiﬁed
a novel association with AD in the adenosine triphosphate (ATP) synthase, Hþ transporting, mitochondrial F0 (ATP5H)/Potassium
channel tetramerization domain-containing protein 2 (KCTD2) locus, which reached genome-wide signiﬁcance in the
combined discovery and genotyping sample (rs11870474, odds ratio (OR)¼ 1.58, P¼ 2.6 10 7 in discovery and OR¼ 1.43,
P¼ 0.004 in Fundacio´ ACE data set; combined OR¼ 1.53, P¼ 4.7 10 9). This ATP5H/KCTD2 locus has an important function
in mitochondrial energy production and neuronal hyperpolarization during cellular stress conditions, such as hypoxia or
glucose deprivation.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia. It
is expected that AD prevalence will be quadrupled by 2040,
reaching a worldwide number of 81.1 million affected individuals.1
In spite of the knowledge that genetic factors may account for
about 60–80% of AD susceptibility,2 the APOE epsilon 4 allele was,
until very recently, the only accepted risk factor for late-onset
AD (LOAD).3 Fortunately, genome-wide association study (GWAS)
technologies are rapidly transforming our knowledge of
susceptibility factors related to LOAD. Speciﬁcally, in the past three
years, nine additional loci located in or adjacent to clusterin (CLU),
PICALM, CR1, BIN1, the MS4A gene cluster, ABCA7, EPHA1, CD33 and
CD2AP, have been identiﬁed.4–9 There is no obvious relationship
between the most of these novel loci and the current models of the
pathogenesis of AD (that is, the amyloid and tau hypotheses), rather
the novel genes identiﬁed point to immune system function,
cholesterol metabolism and synaptic cell membrane processes as
important in determining the risk of LOAD.10 However, researchers
are intensively looking for direct relationships between these novel
loci and amyloid deposition speculating that new genes might have
effects on amyloid metabolism or through previously unsuspected
pathophysiological pathways, and indeed preliminary evidence for
relationships between the amyloid hypothesis and some of the
novel loci is rapidly emerging.11
Speciﬁcally, it has been reported that PICALM has a role in beta-
amyloid membrane trafﬁcking in yeast models;11 Furthermore
using highly sensitive single-molecule ﬂuorescence methods,
Narayan et al. 12 have established a direct link between the CLU
protein and beta-amyloid toxicity, observing that beta amyloid
forms a heterogeneous group of small oligomers (from dimers to
50-mers), all of which interact with the sequestering clu protein to
form long-lived complexes.12
Overall, the known loci explain only a small fraction of the
known heritability of polygenic AD. In this paper, we present the
1Memory Clinic of Fundacio´ ACE, Institut Catala` de Neurocie`ncies Aplicades, Barcelona, Spain; 2Hospital Universitari Vall d’Hebron–Institut de Recerca, Universitat Auto`noma de
Barcelona (VHIR-UAB), Barcelona, Spain; 3Dementia Unit, University Hospital Virgen de la Arrixaca, Murcia, Spain; 4Department of Structural Genomics, Neocodex, Sevilla, Spain;
5Department of Neurology Boston University School of Medicine, Boston, MA, USA; 6Department of Biostatistics, Boston University School of Medicine, Boston, MA, USA; 7Memory
Unit, University Hospital La Paz-Cantoblanco, Madrid, Spain; 8Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; Netherlands
Consortium for Healthy Aging, Leiden, The Netherlands; 9Department of Medicine, University of Washington, Seattle, WA, USA; 10Icelandic Heart Association, Kopavogur
University of Iceland, Kopavogur, Iceland; 11Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institute on Aging, Washington, DC,
USA; 12Alzheimer’s Disease Research Center, Departments of Neurology, Psychiatry and Psychology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 13Centro de
Investigacio´n Biome´dica en Red de Diabetes y Enfermedades Metabo´licas Asociadas (CIBERDEM) Spain, Hospital Clı´nico San Carlos, Madrid, Spain and 14National Heart, Lung and
Blood Institute’s Framingham Heart Study, Framingham, MA, USA. Correspondence: Dr A Ruiz, CSO-cap de recerca, Fundacio ACE, Institut Catala` de Neurocie`ncies Aplicades,
Marque`s de Sentmenat 57, Barcelona 08029, Spain.
E-mail: aruiz@fundacioace.com
15The ﬁrst three authors contributed equally to this work.
16Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). As such, the investigators
within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of
ADNI investigators can be found at: http://adni.loni.ucla.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
Received 20 April 2012; revised 25 May 2013; accepted 30 May 2013; published online 16 July 2013
Molecular Psychiatry (2014) 19, 682–687
& 2014 Macmillan Publishers Limited All rights reserved 1359-4184/14
www.nature.com/mp
results of a collaborative effort to identify additional AD genes. We
followed up on all suggestive (Po0.001) results in our previously
published GWAS (Stage I) with in silico analysis using unpublished
data from a previously reported GWAS in the Cohorts for Heart
and Aging Research in Genomic Epidemiology (CHARGE) con-
sortium (Stage II). Six novel single-nucleotide polymorphisms
(SNPs) that reached a Po5 10 6 were genotyped in an
independent data set (Stage III). This sequential analysis and
novel genotyping allowed us to identify a new AD locus
(adenosine triphosphate (ATP) synthase, Hþ transporting, mito-
chondrial F0/Potassium channel tetramerization domain-contain-
ing protein 2 (ATP5H/KCTD2) at 17q25.1.
PATIENTS AND METHODS
Setting and participants
Stage I meta-GWAS. We followed up the results obtained in our initial
meta-analysis described previously9 Brieﬂy, we undertook GWAS on a
sample of 319 sporadic AD patients diagnosed with possible or probable
AD and 801 population-based controls.13 Due to the limited power of our
sample to detect small genetic effects, we combined our data with the
individual level data from four other publicly available GWAS: TGEN
(Translational Genomics Research Institute; 757 cases and 468 controls),14
ADNI (Alzheimer Disease Neuroimaging Initiative;164 cases and 194
controls),15 genADA (Genotype-Phenotype Alzheimer’s disease Associa-
tions; 782 cases and 773 controls),16 and NIA (Late Onset Alzheimer’s
Disease and National Cell Repository for Alzheimer’s Disease Family Study:
Genome-Wide Association Study for Susceptibility Loci; 987 cases and 802
controls),17 applying identical quality control ﬁlters and the same
imputation methods to each data set and undertook a meta-analysis (for
details see reference9). We also incorporated into this meta-analysis
aggregated genotype data from the Pﬁzer GWAS (Hu et al.;18 1034 AD
cases and 1186 controls) and the GERAD (Genetic and Environmental Risk
in AD) consortium GWAS (Harold et al.;4 3938 AD cases and 7848 controls).
For details, see Supplementary Figure S1.
Stage II: in silico analysis in the CHARGE consortium. We then undertook
an in silico analysis of suggestive hits identiﬁed at Stage I in the CHARGE
consortium data set. The analytic strategies for AD GWAS used by CHARGE
have been published previously.5 Brieﬂy, the CHARGE consortium currently
includes large, prospective, community-based cohort studies that have
GWAS data coupled with extensive data on multiple neurological and non-
neurological phenotypes. A neurology working-group arrived at a
consensus on phenotype harmonization, covariate selection and analytic
plans for within-study analyses followed by meta-analysis of results.5
Informed consent was obtained from all the participants at entry into the
study, and the study protocols were approved by institutional review.
Overall, 1367 AD cases (973 incident) and 12 904 controls from CHARGE
were included in Stage II analysis.
Stage III: de novo genotyping in the Fundacio´ ACE data set. The Fundacio´
ACE data set consisted of 4501 individuals: 2200 possible or probable AD
patients diagnosed by neurologists13 and 2301 healthy controls. The
controls were selected from a Spanish general population available at the
Neocodex bio-bank.19 An additional 122 neurologically healthy controls
were recruited from Fundacio´ ACE as previously described.20 The AD cases
were consecutive patients examined at three recruiting centers: 2032 from
Fundacio´ ACE, Institut Catala` de Neurocie`ncies Aplicades (Barcelona,
Catalonia, Spain), 161 from Unidad de Memoria, Hospital Universitario La
Paz-Cantoblanco (Madrid, Spain) and 7 from Unidad de Demencias,
Hospital Universitario Virgen de la Arrixaca (Murcia, Spain). None have
genome-wide genotype data available.
In order to avoid population stratiﬁcation issues, both cases and controls
were selected to be of white Mediterranean ancestry with registered
Spanish ancestors (for two generations). Demographic characteristics of
the Fundacio´ ACE data set are reported in Supplementary Table S1. Written
informed consent was obtained from all the individuals included or their
representatives when necessary. The referral centers’ ethics committees
have approved this research protocol that is in compliance with national
legislation and the Code of Ethical Principles for Medical Research
Involving Human Subjects of the World Medical Association.
Methods
In silico analyses and selection of SNPs for genotyping follow-up. The
procedure to select candidate SNPs is detailed in Supplementary Figure S1.
Brieﬂy, we designed a multi-stage strategy to prioritize SNPs for further
de novo genotyping in the Fundacio´ ACE data set. In the ﬁrst stage, we
selected a relatively large number of SNPs by establishing a permissive
cutoff in our original meta-GWAS (Po0.001).9 A total of 1202 SNPs met this
threshold, and results for these SNPs were meta-analyzed with results from
the CHARGE GWAS. Thirty-ﬁve SNPs with Po5 10E 6 in the joint analysis
were selected for follow-up and mapped in the UCSC genome browser.21
Twenty-eight SNPs located within known AD loci were excluded. Seven
novel SNPs reaching a predetermined suggestive p-value (Po5 10 6)
but outside known loci were selected for the ﬁnal genotyping step in the
Fundacio´ ACE data set. Of note, based on 1000 genomes data, we
observed that two markers (rs2896209 and rs4406992) were physically
close and displayed strong linkage disequilibrium (LD; 20 bp distance,
r2¼ 0.950). We decided to analyze only one of them. Consequently, the
rs2896209 SNP within SLC24A4 locus was excluded due to strong LD with
and close proximity to the rs4406992 marker (Supplementary Figure S1).
So, we ﬁnally selected six SNPs within new candidate regions for further
follow-up. The sample size, the effective sample size, the data sets that
were informative and the genotype status (imputed or genotyped) for
each selected marker are detailed in Supplementary Table S2.
Genotyping. Selected candidate SNPs were genotyped in the Fundacio´
ACE data set using real-time PCR coupled to ﬂuorescence resonance energy
transfer. Brieﬂy, we extracted DNA using Magnapure technology (Roche
Diagnostics, Mannheim, Germany). Of note, all samples were centralized
and processed in the same location (Neocodex DNA Laboratory, Seville,
Spain). Identical DNA extraction methods, quality controls, equipment and
personnel were applied for the entire genotyping project. Primers and
probes designed for genotyping protocols are summarized in
Supplementary Table S3. The protocols were performed in the LightCycler
480 System instrument (Roche Diagnostics). PCR reactions were performed
in a ﬁnal volume of 20ml using 20ng of genomic DNA, 0.5mM of each
ampliﬁcation primer, 0.20mM of each detection probe and 4ml of LC480
Genotyping Master 5X (Roche Diagnostics). We used an initial denaturation
step of 95 1C for 5min, followed by 45 cycles of 95 1C for 30 s, 56 1C for 30 s
and 72 1C for 30 s. Melting curves were 95 1C for 2min (ramping rate
4.4 1C s 1), 45 1C for 30 s (ramping rate of 1 1C s 1) and 70 1C for 0 s
(ramping rate of 0.15 1C s 1). In the last step of each melting curve, a
continuous ﬂuorimetric register was performed by the system at one
acquisition register per each degree Celsius. Melting peaks and genotype
calls were obtained by using the LightCycler480 software (Roche). In order
to conﬁrm genotypes, selected PCR amplicons were bi-directionally
sequenced using standard capillary electrophoresis techniques.
Statistical analysis. Association analyses in Stage I were carried out using
an allelic association test model with no covariates, as implemented in the
software Plink (http://pngu.mgh.harvard.edu/Bpurcell/plink), to obtain
unadjusted estimates of the effect size and P-values.22 We selected SNPs
only from the autosomal chromosomes. X, Y and mitochondrial SNPs were
excluded. The ﬁlters for genotyping completeness, imputation quality,
minor allele frequency have been described previously.9 Brieﬂy, SNPs were
selected to have a call rate 495% (in each case, control and combined
group, within each data set), and a minor allele frequency 41% (again in
each case, control and combined group, within each data set). SNPs that
deviated grossly from Hardy–Weinberg equilibrium (P-value o10 4) in
control samples were removed. We also removed SNPs with a signiﬁcantly
different rate of missingness (P-value o5 10 4) between case and
control samples within each data set.
Meta analyses in Stages I, II and III were conducted using inverse
variance method (ﬁxed effects model) and random effects model in
PLINK’s ‘meta’ option.22 We presented random effects meta-analysis results
only when heterogeneity was observed (Q-test was statistically signiﬁcant).
The original GWAS in Stage I were treated as separate studies, CHARGE
GWAS results were treated as a single additional study. The weighting of
each study was calculated using the estimated s.e. Genome-wide
signiﬁcant and highly suggestive p-value thresholds were established at
Po5 10 8 and Po5 10 6, respectively.
Final meta-analysis results and Forest plot for rs11870474 showing
association results in the original meta-GWAS, the CHARGE data and the
Fundacio´ ACE data set were derived using the Stata 10.0 (College Station, TX,
USA) ‘metan’ command. Global p-values were calculated in different ways
using PLINK or Episheet software (academic software non-commercial).
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Multivariate logistic regression models were used to adjust the effect
estimates for our top SNP, rs11870474, using age, sex and/or principal
components (PCs) and the presence of APOE E4 as covariates in data sets
wherein these data were available. These analyses were conducted in SPSS
18.0 software (IBM, Armonk, NY, USA) evaluating a dominant model for the
minor allele (CC vs CAþAA genotypes).
Power calculations were done with Episheet spreadsheet (http://www.
drugepi.org/links/downloads/episheet.xls). The basic idea was to calculate
minimum sample size necessary to have 80% power to detect a moderate
effect of rs11870474 SNP assuming z-alpha¼ 1.96, case/control ratio¼ 1,
exposure prevalence 3% and different odds ratio (OR) effects (1.43 and 1.53).
Graphical Representation of Relationships (GRR) software was used to
estimate identity by state (IBS) mean values in all individual pairs and
visualize the resulting relationships. Any potential duplication or cryptic
relatedness across samples was also explored using PLINK or GRR.23
Individual IBS mean values were calculated to identify samples with
common ancestors. In Murcia data set, we found two possible sibling pairs
(IBS 1.63–1.67), and one possible second-degree pair (IBS 1.50), while the
remaining individuals represented a cluster of diverse ranges of relatedness.
Therefore, three individuals were removed to eliminate these relationships.
We also found two possible pairs of ﬁrst-degree relatives (IBS¼ 1.63–1.70)
in the ADNI data set, who were also removed from the analysis. We do not
need to remove any subject from the NIA, TGEN or GenADA studies
(IBSo1.50 in all individuals). However, when relatedness was explored
across these databases, we detected 15 samples that might be duplicated
and 6 related individuals. These were patients from the Mayo clinic (TGEN),
GenADA and ADNI data sets who had also been included in the NIA GWAS
(Supplementary Table S12). The potential impact of this unexpected
ﬁnding, undetected in our previous report, was evaluated separately. In fact,
after removing detected duplications we re-calculated effect sizes and
P-values that varied only at the thousandth and millionth levels,
respectively (data not shown). We concluded that undetected sample
redundancy in our original GWAS has little impact on our results.
LD analyses and proxy searches were conducted using SNAP software
(academic software non-commercial)24 (CEU 1000 genomes information,
500 kb window and r240.7).
Graphic software and other informatics tools. Regional plots containing
meta-GWAS results were generated using LocusZoom (academic software
non-commercial).25 Stage II Manhattan plot was generated using Haploview
software26 (academic software non-commercial; Supplementary Figure S2).
Q–Q plots and inﬂation factor were calculated using SPSS 18.0. A minimal
inﬂation of statistics was observed using ﬁxed effects model meta-analysis
(lambda¼ 1.05). In contrast, a clear deﬂation was observed for the random
effects model (lambda¼ 0.84), demonstrating that this strategy is over-
conservative (Supplementary Figure S3). PC scatterplots were generated
using SPSS 18.0.
RESULTS
The top 1202 SNP (Po0.001) signals obtained in our meta-analysis
previously published9 (Supplementary Figure S1 and
Supplementary Table S4) were submitted to the CHARGE
consortium for further in silico analysis. We received ORs with
95% conﬁdence interval (CI) and risk allele information for 1142/
1202 (95%) of the requested markers. The rest of markers (58
SNPs, 5%) were not available in the CHARGE consortium GWAS
results, because they did not meet pre-speciﬁed quality control
criteria; hence these were excluded from our Stage II meta-
analysis. Of note, effect estimates were calculated without any
modiﬁcation of published methodologies.5,9 Then, we combined
data from each data set using the meta-analysis tool in PLINK
generating a novel SNP list with top signals in terms of effect size
and direction. Finally, we mapped the signals using the UCSC
genome gateway (http://genome.ucsc.edu/) and measured
physical distance and LD with known loci with SNAP software.
(Supplementary Figure S1 and Supplementary Table S5).
A total of 35 SNPs reached our pre-established threshold for
being labeled highly suggestive (Po5 10 6) in the GWAS; these
are listed in Supplementary Table S5. Of note, 16 of these 35 SNPs
reached our pre-established threshold for GW signiﬁcance
(Po5 10 8), but all signals belonged to known AD loci,
including eight SNPs at the APOE locus, MS4A gene cluster (four
SNPs, the most signiﬁcant being rs1562990, P¼ 5.05 10 10),
PICALM (three SNPS, the most signiﬁcant being rs536841, P¼ 9.67
 10 10) and BIN1 (rs744373, P¼ 2.13 10 9).
The remaining 19 SNPs that reached pre-established highly
suggestive P-value thresholds also included 12 markers near known
AD loci such as PICALM (rs2077815), CLU/APOJ (rs569214), CR1
(rs3818361), BIN1 (rs11685593 and rs7561528) and, again, the APOE
chromosomal region (7 markers). Of note, another SNP, rs16871253,
was located within the NEDD9 gene. This locus has been previously
proposed for AD27 (Supplementary Table S5).
The list also included seven SNPs, comprising ﬁve different
chromosomal regions not previously associated with AD
(Supplementary Table S5). Speciﬁcally, we detected the strongest
signal at the ATP5H/KCTD2 locus (rs11870474, P¼ 2.65 10 7)
in a region previously associated with the information processing
speed cognitive phenotype.28 The next strongest signal
corresponded to two markers located within the SLC24A4
gene (rs4406992, P¼ 9.54 10 7; rs2896209, P¼ 4.47 10 6).
The third signal was a synonymous cSNP in exon 2 of
the cholinergic receptor, nicotinic, alpha 9 gene (rs10022491,
P¼ 2.51 10 6). The fourth was an intragenic marker in the
utrophin gene (rs2473130, P¼ 3.50 10 6). The last SNP,
rs11151137 (P¼ 4.05 10 6), is located in an 800-Kb gene
desert at 18q22.1.21
We have previously conﬁrmed, using the Fundacio´ ACE data set,
all the GWAS-signiﬁcant loci detected in this study (APOE, MS4A,
BIN1 and PICALM) and also previously known loci classiﬁed as highly
suggestive in our SNP list (CR1 and CLU).5,9,29 Consequently, we
decided to genotype in the Fundacio´ ACE data set only the ﬁve new
suggestive loci (at CHRNA9, UTRN, SLC24A4, ATP5H/KCTD2 and the
within the gene desert at chromosome 18) and NEDD9. We decided
to follow up the NEDD9 marker because that gene, while previously
described as probably associated with AD in one study, has not
been conﬁrmed at a genome-wide signiﬁcance level to date. We
achieved a nominally signiﬁcant signal only for rs11870474 at the
ATP5H/KCTD2 locus (OR¼ 1.43, 95% CI (1.12–1.83), P¼ 0.0038). The
involvement of the other signals in determining risk of AD remains
uncertain after our attempted validation and will require further
research (Supplementary Table S6).
The rs11870474 signal remained statistically signiﬁcant even
after applying Bonferroni’s multiple testing correction for the six
markers genotyped during the last stage of our study (P¼ 0.0083)
and its effect size remained almost unchanged after covariate
adjustments (OR¼ 1.40, 95% CI (1.08–1.82), P¼ 0.01, dominant
model). Of note, the magnitude of the effect is quite large and
consistent across studies, with all six estimates ranging between
1.31 and 1.85 (see Figure 1). Fixed effects model meta-analysis
with all available data sets conﬁrmed this as a novel GWAS
NOTE: Weights are from random effects analysis
Overall  (I−squared = 0.0%, p = 0.918)
ID
CHARGE
ADNI
NIA
Study
Replica
Murcia
Hu
cases
1367
164
987
2200
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1034
controls
12904
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2301
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1186
1.53 (1.33, 1.77)
Ratio (95% CI)
1.58 (1.24, 2.01)
1.46 (0.60, 3.57)
1.64 (1.06, 2.54)
Odds
1.43 (1.12, 1.83)
1.31 (0.78, 2.20)
1.85 (1.17, 2.93)
100.00
Weight
35.13
2.57
10.80
%
34.02
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Figure 1. Fixed effects model meta-analysis and Forest plot of
rs11870474, reporting odds ratio (OR) with 95% confidence interval
(CI). ADNI, Alzheimer Disease Neuroimaging Initiative; NIA, National
Institute on Aging.
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signiﬁcant locus for AD (Figure 1, OR¼ 1.533, 95% CI (1.329–1.770),
P¼ 5.07 10 9).
DISCUSSION
We present additional results from a GWAS generated by our
group,9 this time following up on selected top markers in a large
independent GWAS generated by the CHARGE consortium.5 After
adding CHARGE information, we conﬁrmed seven different SNPs
identical to those previously reported (Supplementary Table S5).
However, we cannot consider these independent replications,
because some data sets used here overlap with previous studies.
We also detected 21 unreported SNPs within previously described
loci. Overall, most of the newly identiﬁed SNPs are physically close
to previous detected signals (300 kb window) (Supplementary Table
S7). These new markers might help to reﬁne the association at the
previously identiﬁed loci and aid the search for functional variants.
Importantly, by merging results of a meta-GWAS conducted by
our group, results in the CHARGE consortium data sets and an
in vivo genotyping comprising 4501 individuals, we were able to
detect a novel gene associated with AD risk. Compared with the
previous meta-GWAS,5,7,8 our study had information on an
additional 8000 individuals, including the Fundacio´ ACE data set
and data derived from Pﬁzer’s GWAS.18 The larger sample size of
24 227 persons might be one reason why we detected this novel
signal, which was not observed in previous GWAS. The in vivo
genotyping of over 4500 persons was an additional strength
of our study design that permitted the signal to reach the
pre-established GWAS signiﬁcance threshold.
As the new locus reaches genome-wide signiﬁcance only when
including the ﬁnal discovery sample (Stage III), it must still be
considered a highly probable ﬁnding but not a replicated locus.
Independent replications are still required to corroborate this
signal. The low frequency of the rs11870474 marker must be taken
into account for future replication efforts (Supplementary Table
S11). We estimate that a sample size of more than 2450 cases and
an equal number of controls will be necessary to reach 80% power
to detect its observed effect on AD risk (z-alpha¼ 1.96, case/
control ratio¼ 1, exposure prevalence 3% and OR effect
level¼ 1.53). If we consider adjustment for a possible winner’s
curse effect,30 which in fact was observed in the Fundacio´ ACE
data set (decreasing observed effect size to 1.43), the number of
cases necessary to detect this effect (80% power) could rise to
3660 AD cases. So, it is only by using very large case-control data
sets that one can expect to have reasonable power to replicate
this observation.
As age/sex data were not available for some data sets, we
decided to apply homogeneous criteria to available data sets
during Stage I. A potential criticism of our study design emerged
from this decision based on our use of young, general population
controls, as a proportion of these controls might develop AD as
they age. However, although this misclassiﬁcation might reduce
our power to detect an association, it should not create a spurious
association. Furthermore, age- and sex-adjusted logistic regression
analyses in data sets with covariate data available demonstrated
little difference in terms of effect size or statistical signiﬁcance.
(Supplementary Table S10a). Of note, association reported in the
CHARGE data set did include age, sex and PC adjustments,5 and
the effect size observed in this data set was remarkably consistent
with our Stage I result. A second criticism might be that having
controls that are younger than cases might lead to a spurious
association with longevity-related genes. However, our discovery
sample was largely age-matched for cases and controls and the
observed association in the Fundacio´ ACE data set was weaker
rather than stronger making it unlikely that the detected locus
represents a spurious association with longevity rather than AD.
We used this same set of cases and general population controls to
successfully replicate relatively ‘modest’ effects associated with
uncontroversial SNPs located in PICALM, BIN1 and CLU loci.5 We
also detected a consistent signal in the MS4A gene cluster
previously reported by others.7–9 Notably for these known
markers, the observed magnitude of the effect was virtually the
same as that reported in the original studies. Furthermore, general
population controls have some advantages over neurologically
healthy elderly controls, as the latter represent a group of healthy
survivors who escaped infectious, cardiovascular and neoplastic
diseases. Using such ‘hypernormal’ controls might jeopardize the
generalizability of the risk estimates observed and has been
identiﬁed as a potential source of bias.31,32
Another source of bias could be hidden population stratiﬁcation
affecting the rs11870474 results. We have calculated adjusted
effect estimates using two major eigenvectors in three data sets
from Stage I with genomewide genotypic data available
(Supplementary Table S10b). This analysis revealed little impact
of PCs in terms of effect size (OR¼ 1.49, (1.05–2.13), P¼ 0.02; with
three data sets). Of note, the lack of impact of population
stratiﬁcation in our results was also re-enforced by the absence of
correlation between PCs and rs11870474 A-allele carrying status
(Pearson’s determination coefﬁcient (r2)o1.5%) and the homo-
genous distribution of carriers observed in multi-dimensional
scatterplots representing PC1 and PC2 eigenvectors
(Supplementary Figures S5b and S5c). A ﬁnal model integrating
population stratiﬁcation PCs, age and sex was also applied to the
series with these data available (Murcia, ADNI and NIA). Again, little
impact on OR estimates was observed (OR¼ 1.42, (1.003–2.005),
P¼ 0.048). In light of these results, we feel that our observations
cannot be attributed to population stratiﬁcation or correlation
between the rs11870474 marker and age or sex covariates.
Importantly, rs11870474 genotype was directly genotyped in
15 536 individuals comprising four independent data sets and in
half of the CHARGE samples (Supplementary Table S2). Moreover,
we obtained validation data for the imputed genotype in 2147
individuals (from the ADNI and NIA). We observed 99% con-
cordance between genotyped and imputed results using PLINK
software (data not shown), suggesting that imputation process
have been successful for this marker. Furthermore, actual
genotyping data were always preferentially selected when avail-
able (in the NIA, ADNI and Pﬁzer GWAS). Case-control differences in
allele frequency comparing imputed and non-imputed data sets
were almost identical (Supplementary Table S11). These observa-
tions suggest a lack of bias during the imputation process.
The potential signiﬁcance of our ﬁnding is also reinforced by
the independent previous observation that a locus at the same
chromosomal region could also be related to information
processing speed ,which is an important cognitive function
compromised in dementing disorders, and one that might share
a genetic background with other complex cognitive traits, such as
working memory or abstract reasoning.28 However, the marker
previously associated with information processing speed
(rs11077773) only reached a suggestive association P-value
(8.33 10 6).28 Furthermore, in spite of its physical proximity to
rs11870474 (it is only 29 kb away), LD among markers is null
(r2¼ 0.006; D’¼ 1; based on SNAP calculations using 1000
genomes and CEU population). As rs11077773 is not in LD with
rs11870474, it is less likely that there is a direct relationship among
both observations. Rather, it is probable that these two markers
could be tracking different alleles.
The rs11870474 SNP is an intronic non-coding common variant
physically located within the second intron of the KCTD2 gene at
17q25.1 (Figure 2; Supplementary Figure S5). In spite of its small
length (33 kb), this locus is located within a region with low LD; there
are no large LD blocks in this region and this remains true even when
analyzing intragenic markers alone (Supplementary Table S8). This
phenomenon makes it difﬁcult to identify proxy signals around
rs11870474. However, we did detect a proxy marker, rs12943281, just
716bp away from rs11870474 (r2:0.718, D’¼ 1; P¼ 0.008).These
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results are concordant in terms of effect size and p-value with
rs11870474 during Stage I (OR¼ 1.59; P¼ 0.000359 with ﬁve series
for rs11870474 and OR¼ 1.45; P¼ 0.008 with four series for
rs12943281).
Rs11870474 SNP is located within the KCTD2 gene intron 2. This
gene is a member of the KCTD family, which is involved in diverse
functions ranging from DNA transcription33 to degradation of
ubiquitinated proteins and proteasome physiology.34 Other KCTD
functions are related to voltage-dependent potassium channel
function and GABA neurotransmitter receptor B heteromultimeric
composition.35 KCTD2 expression is ubiquitous according to
GeneNote.36 However, the highest levels of expression are noted
in the cerebral cortex and cerebellum.
In spite of these suggestive data, it is important to mention that
another transcription unit, named ATP5H, is embedded in the third
intron of the KCTD2 gene (Supplementary Figure S4). So, the
rs11870474 marker has an alternative candidate gene by position.
This ATP5H gene encodes ATP synthase, Hþ transporting,
mitochondrial F0 (ATP synthase complex V component). Mito-
chondrial ATP synthase catalyzes ATP synthesis, utilizing an
electrochemical gradient of protons across the inner membrane
during oxidative phosphorylation. It is composed of two linked
multi-subunit complexes: the soluble catalytic core, F1, and the
membrane-spanning component, Fo, which comprises the proton
channel. The Fo has nine subunits and the ATP5H gene encodes
the d subunit of the Fo complex.21 Mutations in other members of
the mitochondrial complex V, such as MTATP6, result in Leigh
syndrome characterized by lactic acidemia, hypotonia,
neurodegeneration and MRI (magnetic resonance imaging) brain
lesions (OMIM 256000). So, the ATP5H gene is related to cell
energy production via respiration and its expression is obviously
pervasive. The oxidative stress hypothesis for AD, including
mitochondrial disturbances, is well documented,37 and recent
studies have conﬁrmed that AD cases have signiﬁcantly lower
expression of the nuclear genes (including the ATP5H gene)
encoding subunits of the mitochondrial electron transport chain
in different regions of the brain.38,39
In any case, KCTD2, ATP5H or both together (as these are
probably highly co-regulated loci) are very attractive candidates for
AD risk as both are related to fundamental neuronal physiological
processes associated with tolerance to hypoxia and other stressors.
In fact, potassium conductance alteration and abolition of ATP
synthesis are early events necessary to maintain neuronal survival
during oxygen deprivation.40 However, taking into account avail-
able data, we cannot decide whether KCTD2, ATP5H, a common
variant altering the transcription of either or even other adjacent
genes could explain the observed associations. In fact, a close
marker, rs9907177, has been described as an exon-quantitative trait
loci (eQTL) for the growth factor receptor-bound protein 2 (GRB2)
gene. Interestingly, the GRB2 gene has been proposed as a
candidate for AD. However, this eQTL marker is not associated with
LOAD in our series (P¼ 0.23, three studies) and its LD with
rs11870474 is almost null (D’¼ 1, r2¼ 0.037). Therefore, it seems
unlikely that rs9907177 can explain the observed association.
We also looked for annotated functional variants around
rs11870474 using SNAP software (Supplementary Table S9). We
failed to identify any obvious candidate functional variant linked to
rs11870474 within a 500-kb radius. Interestingly, this analysis
identiﬁed ICT1, HN1 and SLC16A5 genes as potential candidates
explaining our observations. In fact, we observed moderate LD
between the detected signal and some intronic SNPs within these
genes. The ICT1 gene was recently reported to be a component of
the human mitoribosome essential for cell viability.41 HN1 encodes
hemopoietic- and neurological-expressed sequence-1 involved in
neuronal regeneration.42 SLC16A5 gene is a mono-carboxylate
transporter similar to MCT1, which had been involved in mediating
axon damage.43 So, we conclude that other potentially interesting
genes are present at this locus. To delineate a more precise
hypothesis, further research using next-generation sequencing and
detailed functional studies will be necessary.
Finally, it is important to mention that almost all the conﬁrmed
new loci identiﬁed to date have been unveiled using compre-
hensive meta-analyses of multiple GWAS and further genotyping
on independent series. Given the large numbers of individuals
needed to detect this association, it seems likely that we will only
be able to discover more markers with international cooperative
efforts that incorporate larger GWAS data sets with an increased
SNP density.
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